The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?
Open accessAbstract
SUMMARY: Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and cognitive loss, and represents the leading cause of dementia in elderly people. Besides the complex biochemical processes involved in the neuronal degeneration (formation of senile plaques containing Aβ peptides, and development of neurofibrillary tangles), other molecular and neurochemical alterations, like cholinergic deficit due to basal forebrain degeneration, also occur. Because acetylcholine has been demonstrated to be involved in cognitive processes, the idea to increase acetylcholine levels to restore cognitive deficits has gained interest (the so‐called cholinergic hypothesis). This has led to the development of drugs able to prevent acetylcholine hydrolysis (acetylcholinesterase inhibitors). However, the analysis of clinical efficacy of these drugs in alleviating symptoms of dementia showed unsatisfactory results. Despite such critical opinions on the efficacy of these drugs, it should be said that acetylcholinesterase inhibitors, and for some aspects memantine also, improve memory and other cognitive functions throughout most of the duration of the disease. The pharmacological activity of these drugs suggests an effect beyond the mere increase of acetylcholine levels. These considerations are in agreement with the idea that cognitive decline is the result of a complex and not fully elucidated interplay among different neurotransmitters. The role of each of the neurotransmitters implicated has to be related to a cognitive process and as a consequence to its decline. The current review aims to highlight the positive role of cholinergic drugs in alleviating cognitive deficits during wake as well as sleep. Moreover, we suggest that future therapeutic approaches have to be developed to restore the complex interplay between acetylcholine and other neurotransmitters systems, such as dopamine, serotonin, noradrenaline, or glutamate, that are likely involved in the progressive deterioration of several cognitive functions such as attention, memory, and learning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“This suggests that the deterioration of memory and cognitive functions seen in AD patients is a consequence of the progressive degeneration of cholinergic neurons of the basal forebrain and the loss of cholinergic transmission in the hippocampus and cerebral cortex (cholinergic hypothesis of AD) [2].”
BackgroundBerridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529 · cited 1×
“Dys-regulation of the noradrenergic and/or cholinergic neurotransmission systems may be responsible for arousal and/or cognitive dysfunction associated to a variety of psychiatric disorders, including attention deficit, hyperactivity, sleep–arousal disorder [63,64].”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159 · cited 1×
“mediate toxic effects of glutamate [113,114].”
Dineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462
Noradrenergic modulation of arousal
Berridge, C. W. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.10.013 · Cited by 368
Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia
Stopa, E. G., Volicer, L., Kuo-Leblanc, V., Harper, D., Lathi, D., Tate, B., & Satlin, A. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199901000-00004 · Cited by 265
Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P. L.-H., Francis, P. T., Lasheras, B., & Ramirez, M. J. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.06.007 · Cited by 244
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
Cited by
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S. A., Acuña‐Castroviejo, D., Coto‐Montes, A., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 294
Vladimir-Knežević, S., Blažeković, B., Kindl, M., Vladić, J., Lower-Nedza, A., & Brantner, A. (2014) · Molecules · doi:10.3390/molecules19010767 · Cited by 238
“The leading AD therapeutics involve AChE inhibitors, resulting in increased acetylcholine concentrations in the synaptic cleft and enhanced cholinergic transmission [3,4].”
BackgroundDrug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
“However, this hypothesis is still controversial, largely because of the questionable efficacy of the anti-AD drugs intended to treat acetylcholine deficiency [40].”
BackgroundRole of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117
Alterations in the histaminergic system in Alzheimer's disease: a postmortem study
Shan, L., Bossers, K., Unmehopa, U., Bao, A.-M., & Swaab, D. F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.026 · Cited by 84
Metadata
- Authors
- Martorana, A., Esposito, Z., & Koch, G.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2010-07
- Volume
- 16
- Issue
- 4
- Pages
- 235-245
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2160371310
- Cited by
- 174
- References
- 15
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease? https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00175.x
- The paper
- Martorana, A., Esposito, Z., & Koch, G. (2010). Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease? CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00175.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.